KR970705400A - 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone) - Google Patents
골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)Info
- Publication number
- KR970705400A KR970705400A KR1019970701532A KR19970701532A KR970705400A KR 970705400 A KR970705400 A KR 970705400A KR 1019970701532 A KR1019970701532 A KR 1019970701532A KR 19970701532 A KR19970701532 A KR 19970701532A KR 970705400 A KR970705400 A KR 970705400A
- Authority
- KR
- South Korea
- Prior art keywords
- bisphosphonic acid
- hormone
- bone active
- bone
- hydroxyethane
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract 7
- 102000003982 Parathyroid hormone Human genes 0.000 title claims abstract 4
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract 4
- 239000000199 parathyroid hormone Substances 0.000 title claims abstract 4
- 229960001319 parathyroid hormone Drugs 0.000 title claims abstract 4
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims abstract 3
- 208000016097 disease of metabolism Diseases 0.000 claims abstract 2
- 208000030159 metabolic disease Diseases 0.000 claims abstract 2
- POKFKRXICZYGRO-UHFFFAOYSA-N OC.OP(O)=O.OP(O)=O Chemical compound OC.OP(O)=O.OP(O)=O POKFKRXICZYGRO-UHFFFAOYSA-N 0.000 claims 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- BLXHXPRHJHWYMB-UHFFFAOYSA-N (2-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid Chemical compound CCCCC(N)C(O)(P(O)(O)=O)P(O)(O)=O BLXHXPRHJHWYMB-UHFFFAOYSA-N 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- WCJADIUJTZRJKN-UHFFFAOYSA-N ClCCl.OP(O)=O.OP(O)=O Chemical compound ClCCl.OP(O)=O.OP(O)=O WCJADIUJTZRJKN-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- WRZPYEDLCNAYOO-UHFFFAOYSA-N P(O)(O)=O.P(O)(O)=O.C1(CCCCCC1)NC Chemical compound P(O)(O)=O.P(O)(O)=O.C1(CCCCCC1)NC WRZPYEDLCNAYOO-UHFFFAOYSA-N 0.000 claims 1
- HNXMPPCTZRWESS-UHFFFAOYSA-N P(O)(O)=O.P(O)(O)=O.ClC1=CC=C(C=C1)SC Chemical compound P(O)(O)=O.P(O)(O)=O.ClC1=CC=C(C=C1)SC HNXMPPCTZRWESS-UHFFFAOYSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- -1 phosphonate compound Chemical class 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 하기의 단계를 포함하는 골 대사성 질환을 갖는 인간 또는 기타 동물 피검자의 치료방법을 제공한다; (a) 약 6개월 이상의 기간 동안, 골 활성 포스포네이트의 안전 유효량을 피검자에게 투여하는 단계; (b) 약 3 내지 약 12개월의 기간 동안, 부갑상선 호르몬의 안전 유효량을 피검자에게 투여하는 단계.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 하기의 단계를 포함하는 골 대사성 질환을 갖는 인간 또는 기타 동물 피검자의 치료방법;(a)약 6개월 이상의 기간 동안, 골 활성 포스포네이트의 안전 유효량을 피검자에게 투여하는 단계; (b)약 3 내지 약 12개월의 기간 동안, 부갑상선 호르몬의 안전 유효량을 피검자에게 투여하는 단계.
- 제1항에 있어서, 단계 (b)에서, 상기 부갑상선 호르몬을 약 6개월 동안 투여하는 인간 또는 기타 동물 피검자의 치료 방법.
- 제1항에 있어서, 상기 단계 (a)와 (b)를 1 내지 6회 반복하는 인간 또는 기타 동물 피검자의 치료 방법.
- 제3항에 있어서, 단계 (b) 동안 골 활성 포스포네이트를 더 투여하는 것을 포함하는 인가 또는 기타 동물 피검자의 치료 방법.
- 제2항에 있어서, 상기 포스포네이트 화합물이 옥시에탄-1,1-비스포스폰산; 디클로로메탄 비스포스폰산; 3-아미노-1-히드록시프로판-1,1-비스포스폰산; 6-아미노-1-히드록시헥산-1,1-비스포스폰산;4-아미노-1-히드록시부턴-1,1-비스포스폰산; 2-(3-피리딜)-1-히드록시에탄-1,1-비스포스폰산;2-(N-이미다졸릴)-1-히드록시에탄-1,1-비스포스폰산; 3-(N-펜틸-N-메틸아미노)-1-히드록시프로판-1,1-비스포스폰산; 3-(N-피롤리디노)-1-히드록시프로판-1,1-비스포스폰산; N-시클로로헵틸아미노메탄비스포스폰산; S-(p-클로로페닐)티오메탄비스포스폰산; 7-(디히드로-1-피린딘)메탄 비스포스폰산; (7-디히드로-1-피린딘)히드록시메탄 비스포스폰산; (6-디히드로-2-피린딘)히드록시메탄비스포스폰산; 2-(6-피롤로피리딘)-1-히드록시에탄-1,1-비스포스폰산; 및 약제학적으로 허용 가능한 그의 염 및 그의 에스테르로 구성된 군으로부터 선택된 비스포스포네이트인, 인간 또는 기타 동물 피검자의 치료 방법.
- 제5항에 있어서, 상기 비스포스포네이트가 2-(3-피리딜)-1-히드록시에탄-1,1-비스포스폰산인 인간 또는 기타 동물 피검자의 치료 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30392594A | 1994-09-09 | 1994-09-09 | |
| US08/303,925 | 1994-09-09 | ||
| PCT/US1995/011335 WO1996007417A1 (en) | 1994-09-09 | 1995-09-06 | Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970705400A true KR970705400A (ko) | 1997-10-09 |
Family
ID=23174289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970701532A KR970705400A (ko) | 1994-09-09 | 1995-09-06 | 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone) |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0779812A4 (ko) |
| JP (1) | JPH10505090A (ko) |
| KR (1) | KR970705400A (ko) |
| CN (1) | CN1157565A (ko) |
| AU (1) | AU686458B2 (ko) |
| CA (1) | CA2199252A1 (ko) |
| IL (1) | IL115224A0 (ko) |
| WO (1) | WO1996007417A1 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| CN1272013C (zh) | 2000-06-20 | 2006-08-30 | 诺瓦提斯公司 | 二膦酸盐在制备用于治疗骨更新异常增加的病症的药物中的应用 |
| WO2007059470A2 (en) | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CA2769633C (en) | 2009-07-31 | 2017-06-06 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3583887D1 (de) * | 1984-04-30 | 1991-10-02 | Procter & Gamble | Ausruestung fuer die behandlung der osteoporose. |
| US4812304A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Treatment of osteoporosis |
| US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| US4868164A (en) * | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| RU2112515C1 (ru) * | 1991-12-17 | 1998-06-10 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Способ лечения остеопороза |
| US5403824A (en) * | 1993-03-19 | 1995-04-04 | The Procter & Gamble Company | Methods for the treatment of osteoporosis |
-
1995
- 1995-09-06 EP EP95932426A patent/EP0779812A4/en not_active Ceased
- 1995-09-06 KR KR1019970701532A patent/KR970705400A/ko active IP Right Grant
- 1995-09-06 CA CA002199252A patent/CA2199252A1/en not_active Abandoned
- 1995-09-06 JP JP8509664A patent/JPH10505090A/ja active Pending
- 1995-09-06 WO PCT/US1995/011335 patent/WO1996007417A1/en not_active Application Discontinuation
- 1995-09-06 CN CN95195007A patent/CN1157565A/zh active Pending
- 1995-09-06 AU AU35475/95A patent/AU686458B2/en not_active Ceased
- 1995-09-08 IL IL11522495A patent/IL115224A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL115224A0 (en) | 1995-12-31 |
| JPH10505090A (ja) | 1998-05-19 |
| AU686458B2 (en) | 1998-02-05 |
| CA2199252A1 (en) | 1996-03-14 |
| WO1996007417A1 (en) | 1996-03-14 |
| EP0779812A4 (en) | 1997-09-10 |
| AU3547595A (en) | 1996-03-27 |
| CN1157565A (zh) | 1997-08-20 |
| EP0779812A1 (en) | 1997-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5366965A (en) | Regimen for treatment or prophylaxis of osteoporosis | |
| DE69218624D1 (de) | Behandlung von peridontalkrankheiten mit alendronat | |
| AU693541B2 (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| JPH08505142A (ja) | 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法 | |
| RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
| ATE289199T1 (de) | Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten | |
| ATE210643T1 (de) | Prostaglandin-analoga zur behandlung von osteoporose | |
| HUP0204114A2 (hu) | Bifoszfonáttartalmú parenterális gyógyászati készítmény | |
| RU93054017A (ru) | Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза | |
| JPH07502507A (ja) | ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 | |
| FI110667B (fi) | Menetelmä farmaseuttisen valmisteen valmistamiseksi | |
| NO933044D0 (no) | Fremgangsmaate for behandling av osteoporose | |
| BG100911A (en) | Biophosphonic acids-sontaining wet-granulated form | |
| KR970705400A (ko) | 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone) | |
| CA2294101A1 (en) | A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor | |
| DE01201913T1 (de) | Methoden zur Hemmung der Knochenresorption | |
| KR970061249A (ko) | 골다공증을 치료 또는 방지하기 위한 조성물 | |
| KR970705399A (ko) | 골다공증용 포스포네이트 및 부갑상성 호르몬(phosphonates and parathyroid hormone for osteoporosis) | |
| RU2004122433A (ru) | Способ лечения костных нарушений | |
| JP2000504718A (ja) | 骨吸収を予防するための局所用ビスホスホネート | |
| CA2183764C (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| CO4410200A1 (es) | Metodos para el tratamiento de osteoporosis usando fosfona- tos activos de huesos y hormonas paratiroidales | |
| MXPA96005327A (en) | Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| NORF | Unpaid initial registration fee |